Neuracle sells non-invasive neurophysiology equipment including EEG acquisition and transcranial stimulation systems, while developing invasive products for indications including quadriplegia, epilepsy and stroke. Its prospectus brings product stages, clinical progress, capacity plans and financial data into a regulated public disclosure.
Exchange acceptance only starts the review. Neuracle must still pass inquiries, listing review and registration, and both the fundraising amount and project plan may change before any offering.